A recent systematic review published in Annals of Internal Medicine showed inconsistent findings between observational and randomized studies on the impact of tissue-based genomic classifier tests on ...

Incorporating mpMRI in MIBC staging reduces time to treatment, halving it from 98 to 53 days. The mpMRI-first approach avoids unnecessary surgeries, saving costs and surgical resources. The trial ...

Intracutaneous ICG injection with fluorescent laparoscopy improves visualization and accuracy of pelvic lymph node dissection in radical cystectomy. The ICG method significantly reduces operative ...

Annual cost analyses suggest that some newer therapies may have higher up-front costs but can be more economical in the long run due to fewer recurrences and less frequent administration. How does the ...

"The approach is often to identify what treatments the patients have tried already, so we don't try those again, and then have a discussion about the pros and cons," says J. Quentin Clemens, MD, MSCI.

What is your approach to discussing treatment options with patients, especially when considering the long-term financial impact of different therapies? With all the available treatments on market, ...

"At Mayo Clinic, we think that delivering intravesical therapy for non-muscle invasive bladder cancer in patients' homes has the potential to reduce treatment burden, improve the patient experience, ...

Ashish M. Kamat, MD, MBBS, provides expert insights into the current state of bladder cancer care, emphasizing the critical role of patient-centric approaches and exploring the evolving treatment ...

According to Sanda, future advancements may involve gene and RNA sequencing, the use of AI in imaging, and multidisciplinary collaboration. In this video, Martin G. Sanda, MD, highlights key areas of ...

"There is new technology emerging for skin stimulation of the perineum that is just recently evolving to help control OAB symptoms," says Anne Pelletier Cameron, MD, FRCSC, FPMRS. In this video, Anne ...

The combination of belzutifan and cabozantinib showed promising antitumor activity in treatment-naïve ccRCC patients, with a 70% objective response rate and 98% disease control rate. Median duration ...

Optilume provides durable, long-term relief for urethral strictures, with significant improvements in IPSS, Qmax, and PVR over 5 years. The 5-year freedom from repeat intervention rate was 71.7%, with ...